Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Approves Amgen’s Biosimilar of Humira

By Meg Snyder | September 26, 2016

On Friday, 9/23, the FDA approved the first biosimilar version of AbbVie’s Humira.

Developed by Amgen, Amjevita™ (adalimumab-atto) has been approved to treat the following inflammatory diseases:

  • Moderate-to-severe rheumatoid arthritis
  • Moderate-to-severe polyarticular juvenile idiopathic arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Moderate-to-severe chronic plaque psoriasis
  • Adult moderate-to-severe Crohn’s disease
  • Moderate-to-severe ulcerative colitis

The approval of Amjevita follows in the wake of two Phase 3 studies that each met their primary endpoint (showing clinical equivalence to adalimumab) in patients with severe plaque psoriasis and moderate-to-severe rheumatoid arthritis patients. The most common adverse reactions with Amjevita, according to the FDA, are infections and injection site reactions. 

“Approval of Amjevita is an exciting accomplishment. . . Amjevita holds the potential to offer patients with chronic inflammatory diseases an additional treatment option,” said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen.

AP reports that, in 2015, Humira posted sales of approximately 15 billion and is the second-best selling drug in the world. Humira was approved in December 2002 and accounted for 60 percent of AbbVie’s total revenue in 2015.

It is important to note that Amjevita has been approved as a biosimilar, not as an interchangeable product.

“This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions,” said Janet Woodcock, M.D., Director of the FDA’s Center for Drug Evaluation and Research.

According to FirstWord Pharma:

Novartis’ Zarxio (filgrastim-sndz), a biosimilar of Amgen’s Neupogen (filgrastim) approved in March 2015, was the first biosimilar cleared in the US. Earlier this year, the agency approved Celltrion’s Inflectra (infliximab-dyyb), a biosimilar version of Johnson & Johnson’s and Merck & Co.’s Remicade (infliximab), followed by Novartis’ Erelzi (etanercept-szzs) as a biosimilar version of Amgen’s Enbrel (etanercept) last month.

Amgen’s Amjevita is currently undergoing review by the European Medicines Agency and is one of nine programs included in Amgen’s biosimilar pipeline.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE